Previous Close | 1,583.50 |
Open | 1,579.50 |
Bid | 1,538.00 x 0 |
Ask | 1,650.00 x 0 |
Day's Range | 1,575.00 - 1,600.00 |
52 Week Range | 1,302.60 - 1,725.81 |
Volume | |
Avg. Volume | 9,048,789 |
Market Cap | 65.336B |
Beta (5Y Monthly) | 0.27 |
PE Ratio (TTM) | 13.32 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.64 (4.04%) |
Ex-Dividend Date | Feb 22, 2024 |
1y Target Est | N/A |
In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]
Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.